SILENCE THERAPEUTICS PLC's ticker is SLN and the CUSIP is 82686Q101. A total of 30 filers reported holding SILENCE THERAPEUTICS PLC in Q2 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $966,545 | +78.7% | 98,326 | 0.0% | 0.02% | +41.2% |
Q2 2023 | $540,793 | -8.6% | 98,326 | +3.1% | 0.02% | -5.6% |
Q1 2023 | $591,375 | -99.9% | 95,383 | +19.8% | 0.02% | +20.0% |
Q3 2022 | $786,000,000 | +130.5% | 79,636 | +176.4% | 0.02% | +200.0% |
Q2 2022 | $341,000,000 | – | 28,816 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Aquilo Capital Management, LLC | 1,312,233 | $12,886,128 | 11.68% |
M28 Capital Management LP | 363,800 | $3,572,516 | 4.10% |
TCG Crossover Management, LLC | 2,104,875 | $20,669,873 | 3.04% |
Lombard Odier Asset Management (Europe) Ltd | 3,443,912 | $33,819,216 | 1.73% |
Lynx1 Capital Management LP | 235,787 | $2,315,428 | 1.53% |
Artal Group S.A. | 2,500,000 | $24,550 | 1.05% |
Lombard Odier Asset Management (USA) Corp | 4,057,932 | $33,740,000 | 0.76% |
Deep Track Capital, LP | 1,951,580 | $19,164,516 | 0.74% |
Frazier Life Sciences Management, L.P. | 881,173 | $8,661,931 | 0.58% |
BVF INC/IL | 1,508,416 | $14,827,729 | 0.40% |